Covid-19 Living Data

Study registration: *
Publication Israeli Ministry of Health, *, 2021
Dates: 2020-12-20 to 2021-07-17
Funding: Not reported/unclear
Conflict of interest: *

Methods
Methods	Study design:Cohort Description of participants: All residents aged 16 years and older in Israel Inclusion criteria: residents of Israel (ie, the census population) aged 16 years and older (from Haas, et al) with outcomes assessed between June 20-July 17, 2021 Exclusion criteria: people with previous laboratory-confirmed SARS-CoV-2 infection received only one dose, or had received two doses of BNT162b2 and fewer than 7 days had passed since the second dose (from Haas, et al) Follow-up duration (months): 6.93
Vaccines:	2 doses of BNT162b2, 21 days apart
Variant description :
Variant description :	Variant name: Delta Evidence: Indirect evidence (prevalence of variant in the population: 1 to 99%)
Documents available	Protocol NR Statistical plan NR Data-sharing stated: NR Data accessibility: NR
General comment	Cases from 20 June to 17 July 2021 extracted from a PDF of a presentation from the Israeli Ministry of Health with methods from Haas EJ, et al. Lancet. 2021. 397(10287):1819-1829. Prevalence of Delta variant was not reported but states, "Follow-up period shifted to weeks when delta variant dominated sequenced strains in Israel". Concerns over the lack of adjustment for important confounders, potential exclusion of those who only received one dose or newly vaccinated people, and no pre-defined statistical plan available.